세계의 면역조직화학 시장

Global Immunohistochemistry Market to Reach US$4.5 Billion by 2030

The global market for Immunohistochemistry estimated at US$3.0 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Antibodies, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Equipment segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$824.7 Million While China is Forecast to Grow at 6.6% CAGR

The Immunohistochemistry market in the U.S. is estimated at US$824.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$691.6 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Immunohistochemistry (IHC) Market - Key Trends & Drivers Summarized

Why Is Immunohistochemistry (IHC) Gaining Prominence in Disease Diagnosis and Research?

Immunohistochemistry (IHC) is becoming a critical tool in disease diagnosis, clinical research, and therapeutic development due to its ability to detect specific antigens in tissues using labeled antibodies. This technique combines anatomical, immunological, and biochemical methods to visualize the distribution and localization of specific proteins, providing essential insights into cellular and tissue biology. IHC is widely used in oncology for the detection and classification of tumor cells, enabling pathologists to diagnose various types of cancers, assess the severity of the disease, and determine the best course of treatment. The ability to identify biomarkers such as HER2, ER, and PR in breast cancer, or PD-L1 in lung cancer, helps guide targeted therapies and personalized treatment strategies, making IHC an indispensable tool in modern pathology and precision medicine.

The growing prevalence of chronic diseases, particularly cancer, is one of the primary drivers of the global IHC market. As the global incidence of cancer continues to rise, there is an increasing need for accurate and reliable diagnostic tools that can differentiate between cancer subtypes and predict patient responses to specific therapies. IHC is also extensively used in neuropathology for the identification of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, as well as in cardiovascular and infectious disease research. The technique’s ability to provide spatial and contextual information about protein expression in tissues, combined with its compatibility with a wide range of tissue samples, including biopsies and surgical specimens, is expanding its use across multiple therapeutic areas. As healthcare systems worldwide place a greater emphasis on early disease detection and personalized medicine, the demand for advanced IHC solutions is expected to increase significantly.

What Technological Advancements Are Driving the Evolution and Adoption of Immunohistochemistry?

Technological advancements are revolutionizing the field of immunohistochemistry, making it more accurate, efficient, and accessible for a broad range of applications. One of the most transformative innovations is the development of automated IHC platforms, which automate the entire staining process, from sample preparation and antibody incubation to washing and detection. Automation minimizes human error, ensures consistency, and reduces turnaround times, making IHC more reliable and reproducible. Automated IHC platforms such as the Roche BenchMark series and the Dako Autostainer have become essential tools in high-throughput laboratories, enabling the efficient processing of large numbers of samples while maintaining high diagnostic quality. The integration of digital imaging and analysis software with automated platforms is further enhancing the efficiency of IHC workflows, enabling pathologists to visualize, quantify, and interpret staining patterns with greater precision.

Another significant advancement is the development of multiplex IHC techniques, which allow for the simultaneous detection of multiple biomarkers on a single tissue section. Traditional IHC is limited to the analysis of one or two markers per slide, making it challenging to study complex interactions between different cell types or signaling pathways. Multiplex IHC overcomes this limitation by using multiple primary antibodies, each labeled with distinct chromogenic or fluorescent reporters, to visualize multiple proteins in their native tissue context. This capability is enabling researchers to investigate tumor microenvironments, immune cell infiltration, and biomarker co-expression patterns in greater detail. The development of novel multiplexing technologies, such as sequential staining and barcoding, is further enhancing the utility of IHC in research and clinical applications, supporting the identification of predictive and prognostic biomarkers and advancing our understanding of disease mechanisms.

The incorporation of advanced detection systems, such as polymer-based and nanotechnology-based detection methods, is also improving the sensitivity and specificity of IHC. Polymer-based detection systems eliminate the need for biotin, reducing non-specific binding and background staining, while nanotechnology-based methods enhance signal amplification, enabling the detection of low-abundance proteins with greater clarity. The use of synthetic and recombinant antibodies is improving the consistency and performance of IHC reagents, ensuring that the results are more reliable and reproducible. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in digital pathology is transforming the analysis and interpretation of IHC results. AI-driven image analysis software can automatically identify regions of interest, quantify staining intensity, and classify tissue samples, reducing the burden on pathologists and enabling more accurate and standardized assessments. These technological advancements are not only enhancing the capabilities and reliability of IHC but are also expanding its application possibilities, making it a powerful tool for research, diagnostics, and personalized medicine.

How Are Market Dynamics and Regulatory Standards Shaping the Immunohistochemistry Market?

The immunohistochemistry market is shaped by a complex interplay of market dynamics, regulatory standards, and healthcare trends that are influencing product development, adoption, and commercialization. One of the primary market drivers is the increasing prevalence of chronic diseases, particularly cancer, which is driving the demand for more effective diagnostic and prognostic tools. Cancer is a leading cause of morbidity and mortality worldwide, creating a significant need for accurate diagnostics that can guide treatment decisions and monitor disease progression. IHC is widely used in oncology to detect biomarkers that are indicative of cancer type, grade, and potential response to therapies. The rising adoption of targeted therapies and immunotherapies is further increasing the use of IHC to identify patients who are most likely to benefit from these treatments, supporting the trend toward precision medicine. Additionally, the expanding applications of IHC in areas such as cardiovascular, autoimmune, and neurodegenerative diseases are contributing to the growth of the market.

Regulatory standards and compliance requirements are also playing a critical role in shaping the immunohistochemistry market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional bodies have established stringent guidelines for the development, testing, and commercialization of IHC tests to ensure their safety, efficacy, and reliability. Compliance with these regulations is essential for manufacturers to gain market access and maintain the trust of healthcare providers and patients. The regulatory landscape is evolving to address the complexity of IHC tests, particularly in the context of companion diagnostics, which are used to identify patients who are most likely to respond to specific targeted therapies. Companion diagnostics often require co-development and simultaneous approval with the corresponding therapeutic agent, making the regulatory pathway more complex. The growing use of IHC in personalized medicine is encouraging regulatory agencies to refine their guidelines to ensure that IHC tests provide clinically meaningful information that can support treatment decisions.

Market dynamics such as competition among manufacturers, technological innovation, and healthcare reimbursement policies are also influencing the immunohistochemistry market. The competitive landscape is characterized by the presence of established life sciences companies, diagnostic firms, and specialized reagent providers, each striving to develop novel IHC solutions that offer enhanced sensitivity, specificity, and ease of use. Companies are differentiating themselves through product innovation, the integration of digital pathology and AI technologies, and the ability to provide comprehensive IHC solutions that include antibodies, detection systems, and automated platforms. Healthcare reimbursement policies and coverage decisions by payers are impacting the adoption of IHC tests, as reimbursement often determines the accessibility and affordability of these products. Reimbursement environments vary significantly across regions and are influenced by factors such as the clinical utility of the test, the availability of alternative diagnostic options, and the overall healthcare budget. Navigating these market dynamics and regulatory standards is essential for companies operating in the immunohistochemistry market as they seek to expand their presence and address the unmet diagnostic needs of patients and healthcare providers worldwide.

What Are the Key Growth Drivers Fueling the Expansion of the Immunohistochemistry Market?

The growth in the global immunohistochemistry market is driven by several key factors, including the increasing demand for cancer diagnostics, advancements in IHC technology, and the growing adoption of personalized medicine. One of the primary growth drivers is the rising incidence of cancer, which is creating a significant need for diagnostic tools that can provide detailed information about tumor biology and guide treatment decisions. IHC is widely used in oncology for the detection of biomarkers that can classify tumors, predict disease progression, and identify potential therapeutic targets. The growing use of targeted therapies and immunotherapies is increasing the demand for companion diagnostics, many of which rely on IHC to determine biomarker expression levels and identify patients who are likely to benefit from specific treatments. As the global burden of cancer continues to rise and as the adoption of personalized medicine increases, the demand for advanced IHC solutions is expected to grow.

Another significant growth driver is the ongoing advancement of IHC technology, which is expanding the capabilities and applications of the technique. Innovations such as multiplex IHC, digital pathology, and AI-driven image analysis are enhancing the accuracy, efficiency, and clinical utility of IHC. Multiplex IHC enables the simultaneous detection of multiple biomarkers on a single tissue section, providing a more comprehensive view of the tissue microenvironment and supporting the investigation of complex biological interactions. Digital pathology is transforming the way IHC results are analyzed and interpreted, allowing pathologists to visualize tissue samples on a computer screen, perform quantitative analysis, and share images with colleagues for remote consultation. The use of AI and machine learning is further enhancing the interpretation of IHC results by enabling automated quantification of staining intensity, classification of tissue patterns, and prediction of disease outcomes. These technological advancements are making IHC more powerful and accessible, supporting its adoption in both research and clinical settings.

The increasing focus on personalized medicine is also fueling the expansion of the immunohistochemistry market. Personalized medicine aims to tailor treatment strategies to individual patients based on their unique genetic and molecular profiles. IHC plays a critical role in this approach by providing information on the expression of key biomarkers that are associated with disease prognosis and response to treatment. For example, IHC is used to detect the expression of HER2 in breast cancer, PD-L1 in lung cancer, and CD20 in lymphoma, guiding the use of targeted therapies and immunotherapies. The growing emphasis on personalized medicine is encouraging the development of new IHC assays and companion diagnostics that can support individualized treatment decisions. The integration of IHC with other molecular techniques, such as next-generation sequencing (NGS) and liquid biopsy, is further enhancing its utility in personalized medicine by providing a more comprehensive view of the disease at both the molecular and cellular levels.

Lastly, the expanding applications of immunohistochemistry in research and drug development are contributing to the growth of the market. IHC is widely used in preclinical research to study protein expression and localization, investigate disease mechanisms, and evaluate the effects of potential therapeutic agents on tissues. The technique is also used in clinical trials to assess the pharmacodynamics of new drugs and to identify biomarkers that can serve as surrogate endpoints. As pharmaceutical and biotechnology companies continue to invest in research and development, the demand for IHC reagents, antibodies, and detection systems is expected to rise. Additionally, the increasing use of IHC in disease research beyond oncology, such as in neurodegenerative diseases, cardiovascular disorders, and infectious diseases, is expanding the market’s reach. As demand from key sectors such as oncology, research, and personalized medicine continues to rise, and as manufacturers innovate to meet evolving healthcare needs, the global immunohistochemistry market is expected to witness sustained growth, driven by advancements in technology, expanding applications, and the increasing emphasis on precision diagnostics and targeted therapies.

SCOPE OF STUDY:

The report analyzes the Immunohistochemistry market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Antibodies, Equipment, Reagents, Kits); Application (Diagnostics, Drug Testing); End-Use (Hospitals & Diagnostic Laboratories, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 31 Featured) -

• Abcam PLC
• Agilent Technologies, Inc.
• Bio Sb, Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• MilliporeSigma
• PerkinElmer, Inc.
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • Global Economic Update
  • Immunohistochemistry - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Cancer Diagnostics Drives Growth in Immunohistochemistry Market
  • Expansion of Research in Molecular Pathology Spurs Adoption of Immunohistochemistry Techniques
  • Growth in Focus on Targeted Therapies and Precision Medicine Expands Addressable Market for IHC
  • Role of Immunohistochemistry in Biomarker Detection and Cancer Subtyping Strengthens Business Case for Adoption
  • Growth in Use of IHC for Neurological and Infectious Disease Research Expands Market Opportunities
  • Technological Integration for Multiplexed IHC and Digital Pathology Expands Market Potential
  • Increasing Focus on IHC for Companion Diagnostics in Oncology Expands Addressable Market
  • Role of IHC in Enhancing Tissue-based Diagnostics and Personalized Medicine Strengthens Market Demand
  • Growth in Use of Immunohistochemistry in Drug Development and Clinical Trials Expands Market Reach
  • Growth in Use of IHC for Infectious Disease Detection and Surveillance Fuels Market Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Immunohistochemistry Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Drug Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Drug Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Drug Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Immunohistochemistry by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Rest of Europe Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Rest of Europe 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Rest of Europe Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Rest of Europe 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Rest of Europe Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Rest of Europe 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Asia-Pacific Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Asia-Pacific 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Asia-Pacific Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Asia-Pacific 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Asia-Pacific Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Asia-Pacific 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of World Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of World 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of World Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of World 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of World Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of World 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION